Forma Therapeutics Holdings, Inc. (FMTX) Financial Statements (2026 and earlier)

Company Profile

Business Address 300 NORTH BEACON STREET
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

6/30/2022
MRQ
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 464,226,000633,054,000
Cash and cash equivalent 77,421,000282,689,000
Short-term investments 386,805,000350,365,000
Receivables 11,988,00015,273,000
Prepaid expense 3,549,0004,793,000
Other current assets  1,327,000
Other undisclosed current assets 6,638,000 
Total current assets: 486,401,000654,447,000
Noncurrent Assets
Operating lease, right-of-use asset 22,074,000 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization 13,927,0001,520,000
Long-term investments and receivables 26,047,00012,534,000
Long-term investments 26,047,00012,534,000
Other noncurrent assets 12,612,00012,470,000
Total noncurrent assets: 74,660,00026,524,000
TOTAL ASSETS: 561,061,000680,971,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 29,963,00031,700,000
Taxes payable 70,000301,000
Accounts payable 4,145,0004,295,000
Accrued liabilities 25,748,00027,104,000
Other undisclosed current liabilities 5,125,000 
Total current liabilities: 35,088,00031,700,000
Noncurrent Liabilities
Long-term debt and lease obligation: 27,617,000 
Liabilities, other than long-term debt  1,027,000
Deferred rent credit  1,027,000
Operating lease, liability 27,617,000 
Other undisclosed noncurrent liabilities (27,617,000) 
Total noncurrent liabilities: 27,617,0001,027,000
Total liabilities: 62,705,00032,727,000
Equity
Equity, attributable to parent, including: 498,356,000648,244,000
Common stock 47,000 
Additional paid in capital 728,683,000705,607,000
Accumulated deficit (230,374,000)(57,410,000)
Other undisclosed equity, attributable to parent  47,000
Total equity: 498,356,000648,244,000
TOTAL LIABILITIES AND EQUITY: 561,061,000680,971,000

Income Statement (P&L) (USD)
Annual | Quarterly

6/30/2022
TTM
12/31/2021
12/31/2020
Operating expenses (173,986,000)(124,212,000)
Operating loss: (173,986,000)(124,212,000)
Nonoperating income 1,176,00024,079,000
Investment income, nonoperating 1,176,000767,000
Loss from continuing operations before income taxes: (172,810,000)(100,133,000)
Income tax expense (benefit) (154,000)29,719,000
Loss from continuing operations: (172,964,000)(70,414,000)
Loss before gain (loss) on sale of properties:✕(172,964,000)(70,414,000)
Net loss attributable to parent: (172,964,000)(70,414,000)
Other undisclosed net loss available to common stockholders, basic  (3,736,000)
Net loss available to common stockholders, diluted: (172,964,000)(74,150,000)

Comprehensive Income (USD)
Annual | Quarterly

6/30/2022
TTM
12/31/2021
12/31/2020
Net loss: (172,964,000)(70,414,000)
Comprehensive loss, net of tax, attributable to parent: (172,964,000)(70,414,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: